Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody therapeutics. The company has developed a proprietary XmAb? technology platform that it uses to develop antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The company has developed two stage product candidates: XmAb5871, which is being developed for autoimmune disease; and XmAb7195, which is being developed for asthma and allergic diseases. The company is also developing a pipeline of bispecific antibody candidates including, among others: XmAb14045, which is for the treatment of acute myeloid leukemia.
  • TickerXNCR
  • ISINUS98401F1057
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Multiple Clinical Milestones Expected 2H19

David Nierengarten ...
  • Jeffrey La Rosa

1Q19 Financials; Multiple Clinical Milestones Expected 2H19

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 6, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

A director sold 20,000 shares at 20.612USD and

A director at Xencor Inc sold 20,000 shares at 20.612USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

ValuEngine Rating and Forecast Report for XNCR

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch